-further data from study released December. the safety data should be good as there has no safety concerns to date with the small molecule. according the prospectus, if the drug is recommended for human trials following safety and efficacy data AND share price is over 40c for five days or more it triggers some director share bonus (see prospectus for exact details).
-new 6-8week study combining NYRs cholesterol lowering drug with statin. this will really put a rocket under the sp if positive imo . (the combination worked when tried previously at lower doses so good reason to be optimistic). statins are the world largest selling drugs and are coming off patent so combining it with this will be blockbuster for one of the major players ie. Lipitor Crestor.
some further brain study info expected by mid year which is also potentially huge.
can be given iv or intranasal. intranasal is targeting concussion prevention in sports. as well as having applications in stroke and major head injury.
excellent management and excellent prospects.
it is currently mc 40m which is why I think it is grossly underrated by the market right now.
with the news in the next 1-2 months (q1) and subsequent progress with these proprietary small molecules, this company should be Mc 100m as a starting point.
then with more and more positive data will be 500m plus IMO based on other biotech peer to peer comparison.
so.... massive opportunity here.
NYR Price at posting:
37.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)